Anthelmintic discovery and registration
description
Transcript of Anthelmintic discovery and registration
![Page 1: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/1.jpg)
Anthelmintic discovery and
registration
Nick Sangster
Faculty of Veterinary Science
University of Sydney
![Page 2: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/2.jpg)
Worms
![Page 3: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/3.jpg)
Objectives
• Be aware of research into new modes of action• Explain screening for the discovery of AH• Explain the development process for AH• Detail the important steps in registration• Understand the needs for trials• Describe Good Clinical Practice• Understand the components in the calculation of
withholding periods
![Page 4: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/4.jpg)
Requirements of anthelmintics
• Effective, safe, non toxic to consumer.• Narrow spectrum, broad spectrum• Stock Medicines Act 1989 and vets
– Anyone can give stock medicines to non-food producing animals (we eat horses!)
– Only vets can vary label directions in food producers but MUST supply (in writing) species, withholding, dose rate, frequency of treatment, manner of administration.
– No one can use an unregistered stock medicine except under permit or order
![Page 5: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/5.jpg)
Aspects of commercial anthelmintics
• Establishing a need/market
• Research
• Screening
• Refinement
• Development
• Marketing
• Technical support
![Page 6: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/6.jpg)
Research - pharyngeal pumping
L1 pumping video
![Page 7: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/7.jpg)
5-HT stimulates pharyngeal pumping in T.colubriformis
5HT 10-5M0
0.5
1
1.5
2
2.5
0.01 0.1 1 10 100 1000Concentration (M)
Fre
qu
ency
ind
ex
![Page 8: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/8.jpg)
ICC of H. contortus pharynx
![Page 9: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/9.jpg)
Screening for anthelmintic activity
• Primary in vitro: – Screens are muscle contraction, larval death in
vitro, failure to hatch, loss of motility.– False positives: pineapple juice kills worms in
vitro but is not an anthelmintic– False negatives: some drugs are activated by
host metabolism so are not active in vitro
![Page 10: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/10.jpg)
Screening for anthelmintic activity
• Secondary: – Controlled tests in infected lab animals like mice
• Syphacia• Hymenolepis• Heligosomoides
• Tertiary:– Controlled tests in target animal eg. sheep with
Haemonchus
• Field tests: – Trials with natural infections in target animal in real
environments
![Page 11: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/11.jpg)
Screening for anthelmintic activity
• High throughput screens and combinatorial chemistry– Decide on a target eg. 5-HT action– Proof of concept eg. physiological effects of 5-HT, different
receptor compared with host– Clone, express receptor and develop assay adapted for HTS
(multiwell plate, robotics, automated readout)– Screen 1 million compounds– Take ’hits’ and synthesise better analogues– Move to primary or secondary screens
![Page 12: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/12.jpg)
Development and Registration
Identified compound
Pharmaceutical form
Analyticaltechniques
Teratogeicity
Toxicity
Stability, dose rate, spectrum, safety (rats, target), Presentation, field studies
Efficacy studies
Safety studies
Stability studies
![Page 13: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/13.jpg)
Why we need Registration
• Ensure quality of product
• Ensure safety of product
• Employ Good Clinical Practice
• Define efficacy requirements
• Consider toxicity to the environment
• Check for exposure of humans to drugs
![Page 14: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/14.jpg)
Drug registration and VICH
• International harmonisation of registration• Standard requirements for all countries• Overseen by VICH (US, EU, Japan)• Under the OIE• Align technical requirements• Can use trial & testing data from other countries to
reduce costs• Aim for consistency and safety
![Page 15: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/15.jpg)
Registration of anthelmintics
• Stability testing• Analytical procedures• Bioequivalence • Good Clinical Practice• Specific guidelines available for:
– General requirements– Swine– Equines– Canines– Bovines– Ovines– Caprines
![Page 16: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/16.jpg)
Guidelines for Bovines
• Controlled tests– Egg counts– Worm counts
• Natural or induced infections– Minimum infection rates
• Claims for different species: adults, larvae• Trials
– Two dose confirmation studies– At least 6 animals per group– Animals >3 mo. old and groups randomised– Administration as for product– Significant difference between treated and control– Effectiveness >90%
![Page 17: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/17.jpg)
Other guidelines, for example:
• Can register as “aids in control”• Need 100% efficacy for some parasites like
Echinococcus• Claims for persistent action• Claims for control or protection• Equivalence requires blood level measurements in
blood• Local trails for food producing animals under
different climatic conditions• Monitor for adverse reactions.
![Page 18: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/18.jpg)
Some aspects of “Good Clinical Practice”
• Accuracy, integrity and correctness of data• Standard Operating Procedures for ALL activities• Qualified persons to perform them• Informed consent of owner• Quality control of substances• Independent audit • Record adverse findings• Record keeping and reporting
![Page 19: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/19.jpg)
Withholding
• Withdrawal of animal products from human consumption after treatment
• Important for registration and food export
• Calculated on the persistence of chemicals in animal organs after treatment
![Page 20: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/20.jpg)
Profile of a drug
Log [A]
Timeabsorption
Partitioning (depot)
metabolism
eliminationEfficacy driven by Cmax and time above threshold
Dose rate driven by potency, bioavailability
![Page 21: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/21.jpg)
Calculation of withholding period
• Only applies to food producing animals. • Period before which it is unsafe (illegal) to slaughter
for meat or use milk or eggs for human consumption because of chemical residues.
• For some compounds, there is NO withholding period, meaning the levels in the product never reach threshold levels.
• The withholding period is calculated by considering the drug dose rate, the expected toxic level for humans and the drug elimination kinetics from edible organs.
![Page 22: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/22.jpg)
MRL
• Maximum Residue Level is the highest allowable level in food products.
• Chemicals are eliminated from the body of the animal over time, so it is a matter of waiting long enough.
• There is general harmonisation of levels ‘agreed’ to by Governments, EPA, Food Standards, WHO
![Page 23: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/23.jpg)
Calculation of MRL for drug A for humans eating sheep meat
• Say the dose rate of A in sheep is 0.2 mg/kg.• Let’s say the human ‘no observable effect level’
(NOEL) based on animal studies for A has been determined as 1.25 mg/kg body weight.
• The safety factor applied is generally 200.• So, a the adult daily intake (ADI) is 6 g/kg, 200
fold less than the NOEL.• A 60 kg adult can eat 360 g of A per day.
![Page 24: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/24.jpg)
MRL• A number of sheep are killed at intervals after treatment with A
and the concentration of A is measured in various edible tissues.• By looking at this data you can identify a time (12 +2 days)
where eating the following every day you will, on average, just get your dose (=397 g)Organ [A] kg eaten
Muscle 10 g/kg 0.3Fat 10 g/kg 0.05Liver 100 g/kg 0.1Kidney 10 g/kg 0.05
![Page 25: Anthelmintic discovery and registration](https://reader035.fdocuments.in/reader035/viewer/2022062409/56814af9550346895db80ad2/html5/thumbnails/25.jpg)
MRL and elimination profile of A to determine witholding period
Log [A]
Time
MRL
Witholding period
14 days